Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	12/18/2002 6:33:49 AM
From: nigel bates	of 631

Peptech / anti-TNF Wednesday December 18, 3:42 am ET SYDNEY -(Dow Jones)- Peptech Ltd. , a small Australian biotechnology concern, said Thursday that receipt of official confirmation of another anti-TNF patent should strengthen its hand in resolving a dispute with a major licensee, Centocor Inc. "With regard to the current dispute with Centocor regarding payment of royalties, this additional patent is likely to enhance Peptech's position," it said in a brief statement to the Australian Stock Exchange. Confirmation that a Peptech's anti-TNF, or tumor necrosis factor, patent is to be issued Dec. 24, helps expand the company's patent coverage in the U.S., making it substantially the same as in Europe, it said. In October, Peptech warned that Centocor, a unit of Johnson & Johnson , had stopped paying it royalties for sales of the Remicade arthritis treatment in Europe and refused to begin paying royalties for Remicade sales in the U.S. The disagreement has been referred to a previously arranged dispute resolution process...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next